Literature DB >> 15519520

Inherited cancer in children: practical/ethical problems and challenges.

Marc Tischkowitz1, Elisabeth Rosser.   

Abstract

Over recent years significant molecular advances have led to a better understanding of the genetics of both syndromic and non-syndromic paediatric cancers. In addition many hereditary cancer predisposition syndromes are now recognised, some of which have implications for children in affected families. Improvements in gene mutation screening will increase the sensitivity, accuracy and therefore the applicability of genetic testing in these conditions. This review will deal with four main areas pertaining to paediatric cancer genetics (i) genetic aspects of some non-syndromic paediatric cancers (ii) paediatric cancer predisposition syndromes, (iii) the management of children in families with predominantly adult- onset cancer predisposition syndromes and (iv) special ethical, legal, social and psychological considerations in the management of children, with actual or possible genetic cancer predisposition. Current concepts and controversies in the rapidly changing field of paediatric cancer genetics will be examined in detail and the application of existing guidelines and their limitations will be discussed.

Entities:  

Mesh:

Year:  2004        PMID: 15519520     DOI: 10.1016/j.ejca.2004.06.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  2 in total

1.  Increased incidence of childhood, prostate and breast cancers in relatives of childhood cancer patients.

Authors:  Susanne Magnusson; Thomas Wiebe; Ulf Kristoffersson; Helena Jernström; Håkan Olsson
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

2.  High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort.

Authors:  Gillian Mitchell; Mandy L Ballinger; Stephen Wong; Chelsee Hewitt; Paul James; Mary-Anne Young; Arcadi Cipponi; Tiffany Pang; David L Goode; Alex Dobrovic; David M Thomas
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.